An open label single arm non-comparative study to assess the effectiveness and safety of Melaglow Day and Night cream (combi kit) in the treatment of epidermal hyperpigmentation.

CUTIS Academy of Cutaneous Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1.Female patients, between 18-45 years of age, with epidermal hyperpigmentation.
•2.Participants able to provide a written informed consent
•2.Participants willing to follow up for three visits over a period of 12 weeks (approximately).
•3.Participants able and willing to follow all the study procedures including abstinence from usage of any OTC product related to face applications.
•3.Participants willing to be clinically photographed as per protocol

•1.Patient not willing to participate in the study or comply with any study procedures / requirements.
•2.Patients using other pigment reduction creams.
•3.Patients with other dermatological disorder of the face that may interfere with the study evaluation (Acne, Dermatosis Papulosa Nigra (DPN), Melasma, Seborrheic melanosis)
•4.Patients with known hypersensitivity to any of the study drugs or constituents.
•5.Patients expected to be exposed to the triggering factors during the course of study. (excessive sun exposure, UVB photo therapy, use of oral contraceptive pills (OCPs)
•6.Patient who received facial procedures like dermabrasion, chemical peels or laser procedures within the last 1 month.
•7.History of or ongoing thyroid disorder
•8.Any patient as per investigatorâ??s opinion is unfit for participation in the study.
•9.Pregnant / lactating females

发起方